The new new contracts, who’s behind them, and what they mean — delivered to your inbox every week. No credit card, unsubscribe anytime.
Weekly Digest
New new contracts, summarized for you
Straight to Inbox
No login, no app to check — it comes to you
Contract Trends
See who's moving and how much in your market
No credit card required Weekly contract digest
89bio, Inc. Announces Pricing of $250.0 Million Public Offering of Common Stock and Pre-Funded Warrants
Jan 29, 2025•over 1 year ago
Contract Type
partnership
San FranciscoBiotechnologyHealth CareTherapeuticsPharmaceuticalBiopharma
Description
89bio, Inc. announced the pricing of its upsized underwritten public offering of common stock and pre-funded warrants. The gross proceeds of the offering to 89bio are expected to be approximately $250.0 million.
Company Information
Company
89bio
Location
San Francisco, California, United States
About
89bio is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases. The company’s lead product candidate, BIO89-100, is a specifically engineered glycoPEGylated analog of FGF21. BIO89-100 is being developed for the treatment of nonalcoholic steatohepatitis (NASH) and severe hypertriglyceridemia (SHTG). Recent Phase 1b/2a data show BIO89-100 demonstrated a favorable safety and tolerability profile and robust reductions in liver fat and key lipid markers when dosed weekly or once every two weeks in patients with NASH. BIO89-100 is currently in a Phase 2 trial for the treatment of SHTG.
San FranciscoBiotechnologyHealth CareTherapeuticsPharmaceuticalBiopharma